Nanotechnology and blood brain barrier

Indian Drugs

Volumn 44, Issue 4, 2007, Pages 245-252

  Bachhav, D ^a   Rao, M ^a   Madgulkar, A ^a   Rao, S ^a  

^a AISSMS COLLEGE OF PHARMACY   (India)

Author keywords

Blood brain barrier; Nanoparticles; Polymers

Indexed keywords

EID: 63249119332     PISSN: 0019462X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Kreuter J., Alyautdin R.N., Kharkevich D.A., Ivanov A.A., Passage of peptides through blood brain barrier with colloidal polymer particles (nanoparticles). Brain Res.1995, 674,171-174.
2. Alyautdin R.N.,Gothier D.,Petrov V., Kharkevich D.A., Kreuter J., Analgesic activity of hexapeptide dalargin adsorbed on the surface of polysorbate-80, coated poly (Butyl cyanoacrylate) nanoparticles. Eur. J. Pharm. Biopharm. 1995, 41, 44-48.
3. Wegener J., Galla H.J., The role of non-lamellar lipid structures in the formation of tight junctions. Chem. Phys. Lipids. 1996, 81, 229-255.
4. Minn A., Ghersi-Egea J.F., Perrin R., Leninger B., Siest G., Drug metabolizing enzyme in the brain and cerebral microvessels. Brain Res.Rev. 1991,16,65-82.
5. Kreuter J., David U., Begley J., Michael W. Bradbury; Using nanoparticles to target drugs to the CNS, The Blood Brain Barrier and Drug Delivery to the CNS. Marcel Dekker Inc., New York. 2000, 205-206.
6. Bryan J., Crossing the blood brain barrier:drug delivery to the brain is still elusive.The Pharm. J. 2004, 273(7319), 475-476. (Pubitemid 39378065)
7. National Science and Technology Council, National Nanotechnology Initiative, Washington DC, 2000.
8. Paul J.A.Borm, and Wolfgang Kreyling; Toxicological Hazards of Inhaled Nanoparticles -Potential Implications for Drug Delivery. J.Nanosci. Nanotech. 2004, 4(5), 521-53
9. Labhasetwar V., Song C., and Levy R. J., Nanoparticles drug delivery system. Adv.Drug. Deliv. Rev. 1997, 24, 63-85.
10. Vinogradov S.V., Bronich T.K., Kabanov A.V., Nanosized cationic hydrogels for drug delivery:preparation, properties and interaction with cells, Adv.Drug Del.Rev., 2002, 54,135-147.
11. Guzman L.A., Labhsetwar V., Song C., Jang A.M., Local intraluminalinfusion of biodegradable polymeric nanoparticles.A novel approach for prolonged drug delivery after balloon angioplasty, Circulation, 1996, 94, 1441-1448. (Pubitemid 26307277)
12. I.Brigger I. I., Dubernet C., Couvrecur P.; Nanoparticles in cancer therapy and diagnosis. Drug Deliv.Rev.2002, 54,631-651.
13. Couvreur P,Dubernet C.,Puisieux F.,Controlled drug delivery with nanoparticles:current possibilities and future trends, Eur. J. Pharm. Biopharm., 1995, 41, 2-13
14. Chen G., Double J.A., Bibby M, Chow D.S.L., Characterization of liposomal mimetic formulations for selective targeting, Pharm. Res., 1996, 13(Suppl.), S-161.
15. Al Khouri Fallouh N.,Roblot-Treupel L.,Fessi H.,Devissaguet J.P.,Puisieux F.,Development of a new process for the manufacture of polyisobutylcyanoacrylate nanocapsules, Int. J. Pharm., 1996, 28, 128-132
16. Storm G., Belliot S. O., Daemen T., Lasic D. D.; Surface modification of nanoparticles to appose uptake by mononuclear phagocyte system. Adv. Drug Deliv. Rev. 1995, 16, 195-214.
17. Torchilin V.P.,Trubetskoy V.S; Which particle can make nanoparticulate drug carriers long circulating ? Adv.Drug. Deliv.Rev.1995, 16,141-155.
18. 14Cpoly (methylmethacrylate) nanoparticles in experimental tumor models. Pharm. Res. 2001, 18, 1613-1619.
19. Mageti.N.V., Ravikumar; Nano and Microparticles as a controlled drug delivery devices. J. Pharm. pharmaceut. sci. 2000, 3(2) 234-258.
20. Konan Y. N., Gurny R., Alleman E.; Peparation and characterization of sterile and freeze dried sub-200nm nanoparticles. Int.J.Pharm.2002, 233,239-252.
21. Nishioka Y., Yoshino H.; Lymphatic targeting with nanoparticulate system.Adv.Drug.Deliv.Rev.2001, 47, 55-64.
22. http: // www.exqor.com
23. Swarbrick J., Boylan J. C.; Encyclopedia of pharmaceutical technology-Microsphere technology and application to nuclear magnetic resonance in pharmaceutical technology.Vol.2, Marcel-Dekker Inc: New York. 1994,10,168-173.
24. Chawala J. S., Amiji M. M.; Biodegradable poly (ε caprolactone) nanoparticles for tumor targeted delivery of tamoxifen.Int.J.Pharm.2002, 249,127-138.
25. Troster S. D., Muller U., Kreuter J.; Modification of the body distribution of poly (methyl methacrylate) nanoparticles in rats by coating with surfactants.Int.J. Pharm.1990, 61, 85-110.
26. 14C poly(methylmethacrylate) nanopar ticles. J.microcapsulation.1992, 9, 19-28.
27. Muller R.H., and Keck C.M;Drug delivery to the brain realization by novel drug carriers.J.Nanosci. Nanotech.2004, 4,471-483.
28. Kreuter J; Influence of the surface properties on nanoparticle-mediated transport of drugs to the brain. J.Nanosci.Nanotech. 2004, 4,484-488.
29. Vinogradov S.V., Batrakova E.V., A.V.Kabanov; Nanogels for oligonucleotide delivery to the brain.Bioconjug. Chem.2004, Jan-Feb; 15(1),50-60.
30. Feng S.S.,Mu L.,Huang G.;Nanoparticle technology for drug delivery across the blood-brain barrier,Curr.Med. Chem.2004,11(4),413-424
31. http://nanocancer.gov/news-center/nanotech-news-2005-11-14b.asp
32. Dehouck B.,Fenurt C.,Dehouck M.P.,Pierce A.,Torpier G.,Cecchelli R; A new function for the LDL receptor ; Transcytosis of LDL across the blood brain barrier.J.Cell. Biol.1997,138,887-889.
33. Cordon Cardo C,O'Brien J.P.,Casals D, Rittmann Grauner L, Bidler J.L, Melamed M.R., Bertino J.R; Multidrug resistance gene (p-glycoprotein) is expressed by endothelial cells at blood brain barrier sites.Proc.Natl. Sci.USA.1989,86,695-698.
34. Woodcock D.M,Jeffersons S,Linsenmeyer M.E,Crowther P.J.,Chojnowski G.M,Williams B.,Bertoncello I;Reversal of multidrug resistance phenotype with cremophor EL, a common vehicle for water insoluble vitamins and drugs. Cancer Res.1990,50,4199-4203.
35. Woodcock D.M.,Linsenmeyer M.E.,Chojnowski G.M.,Kriegler A.B.,Nink V., Webster K.,Sawyer W.H;Reversal of multidrug resistance by surfactants. Br.J.Cancer, 1992,66,62-68.
36. Zordan-Nudo T., Ling V., Liv Z., Georges E;Effects of nonionic detergents on p-glycoprotein drug binding and reversal of multidrug resistance.Cancer Res.1993, 53, 5994-6000.
37. Nerukar M.M.,Burto P.S,Borchardt R.T; The use of surfactants to enhance permeability of peptides through caco-2 cells by an inhibition of an apically polarized efflux system.Pharm Res.1996,13,528-534.
38. Müller R.H., Keck C.M.,Drug delivery to the brain Realization by novel drug carriers. J. Nanosci. Nanotech. 2004, 4, 471-483 (Pubitemid 39402941)
39. Paul J.A.Borm And Wolfgang K;Toxicological hazards of inhaled nanoparticle potential implication for drug delivery. J. Nanosci. Nanotech. 2004, 4(5), 521-531.
40. Seaton A.,Macnee W.,Donaldson K.,Godden D;Particulate air pollution and acute health effects,Lancet.1995,345,1 76-178
41. Stone P.H.,Godleski J.J; First steps towards understanding pathologic link between air pollution and cardiac mortality, Am.Heart J.1999, 138,804.
42. Bhalgat M.K.,Hangland R.P.,Pollack J.S.,Swan S., Haugland R.P; Green and red fluorescent nanospheres for the detection of cell surface receptors by .ow cytometry. J.Immunol.Methods.1998, 219, 57-68.
43. http://en.wikipedia.org/wiki/Jurkat-cells
44. Vaisanen V, Harma H., Lilja H., Bjartell A; Time resolved fluorescence imaging for quantitative histochemistry using lanthanide chelates in nanoparticles and conjugated to monoclonal antibodies. Luminescence. 2000, 15, 389-397.
45. Davis S.S., Frier M.,Lllum L;Colloidal particles as radiodiagnostic agents in: P.Guiot, P.Couvreur (Eds), Polymeric Nanoparticles and Microspheres, CRC Press, Boca Microspheres, FL.1986, 175-197.
46. Ghanem G.E.,Joubran C.,Fruhling A.J;Labelled polycyanoacrylate nanoparticles for human invivo. Appl. Radiat. Isot. 1993, 44, 1219-1224.
47. Winser E.R., Katzberg R.W, Link D.P.,Griffey S.M., Drake C.M., Vessely A.R., Ohnson A.R., Haley P.J; Indirected computed tomography lymphography using iodinated nanoparticles to detect cancerous lymph nodes in a cutaneous melanoma model.Acad. Radiol. 1996, 3, 40-48.
48. Winser E.R., Katzberg R.W, Griffey S.M, Jhaley P, Johnson D.K., Vessey A.R; Characterization of normal and cancerous lymph nodes on indirect computed tomography lymphographic studies after interstitial injection of iodinated nanoparticles.Acad.Radiol.1996, 3, S257-S260.
49. Bonnemain B ; Superparamagnetic agents in magnetic resonance imaging; physiochemical characteristics and clinical applications-a review.J.Drug Target. 1998, 6, 167-174.
50. Enochs W.S.,Harsh G., Hochberg F., Weissleder R; Improved delineation of human brain tumors on MR images using long circulating superparamagnetic iron oxide agent. J. Magn. Reson. Imaging. 1999, 9, 228-232